SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Zydus Cadila gets final approval from USFDA for Ziprasidone Hydrochloride Capsules

23 Aug 2017 Evaluate

Zydus Cadila has received the final approval from the United States Food & Drug Administration (USFDA) to market Ziprasidone Hydrochloride Capsules in strengths of 20 mg, 40 mg, 60 mg, and 80 mg.  Ziprasidone, an antipsychotic medication, is used to treat schizophrenia and the manic symptoms of bipolar disorder (manic depression). The drug will be manufactured at the group's formulations manufacturing facility at the Phanna SEZ, Ahmedabad. 

The group now has more than 140 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.

Zydus Lifesciences Share Price

942.55 3.35 (0.36%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×